Rezolute Q4 2026 Earnings Report

Rezolute EPS Results

• Actual EPS: -$0.20
• Consensus EPS: -$0.15
• Beat/Miss: Missed by -$0.05
• One Year Ago EPS: N/A

Rezolute Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Rezolute Announcement Details

• Quarter: Q4 2026
• Date: 9/24/2026
• Time: After Market Closes
• Conference Call Date: Thursday, September 24, 2026
• Conference Call Time: 4:00PM ET

Rezolute (NASDAQ:RZLT) is a clinical-stage biopharmaceutical company focused on developing treatments for rare and metabolic diseases. The company’s research is centered on therapies that address abnormal insulin activity and other conditions involving disrupted glucose regulation.

Rezolute’s leading product candidate is RZ358, an investigational monoclonal antibody designed to reduce the effects of excessive insulin. The therapy is being developed primarily for congenital hyperinsulinism, a rare disorder in which the pancreas produces too much insulin and causes potentially severe, recurrent hypoglycemia. Rezolute has also investigated RZ358 in other forms of hyperinsulinemic hypoglycemia, including conditions associated with insulin-producing tumors.

The company is also developing RZ402, an investigational oral plasma kallikrein inhibitor intended for potential use in diabetic macular edema and other diseases involving vascular leakage. Rezolute conducts its research and development activities through clinical programs and collaborations supporting the advancement of treatments for patients with significant unmet medical needs.

Rezolute is headquartered in Redwood City, California, and was founded by Nevan Elam, who serves as the company’s chief executive officer. Its shares trade on the Nasdaq under the symbol RZLT.